# Multi-Pathogen Vaccine

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/multi-pathogen-vaccine
Canonical HTML page: https://getbiobrief.com/entity/multi-pathogen-vaccine

## Timeline

- **2027-Q3**: Phase I Trials — Anticipated start of first-in-human safety and dosage escalation studies.
- **2027**: IND Filing — Target window for filing an Investigational New Drug application with the FDA.
- **2026-Q4**: Pre-clinical Completion — Expected conclusion of animal model testing and toxicology reports.
- **2026-02-20**: Study Publication — Stanford University researchers publish findings on a multi-pathogen vaccine candidate.

## Recent coverage (1 stories)

### Stanford Breakthrough: Universal Vaccine Strategy Targets Multiple Pathogens
2026-02-20 19:40:08 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2

Researchers at Stanford University have unveiled a novel vaccine candidate designed to provide broad-spectrum protection against a variety of viral infections. This multi-pathogen approach marks a significant shift from traditional strain-specific immunizations toward a more resilient public health defense.
Full story: https://getbiobrief.com/story/stanford-universal-vaccine-multiple-infections

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.